Pharmaceutical giant Eli Lilly has recently announced that it will be revealing date from more than fifty studies at the up and coming 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida from May 29 to June 2 2009
The majority of the presentations will relate to the cancer research studies that Lilly is known for, and the company will also unveil further details about its breakthrough drug Alimta, which has been used to treat cancers including mesothelioma.
Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader, said: “ASCO’s theme of ‘Personalizing Cancer Care’ is one to which Lilly has subscribed for many years. We are focused on delivering what we call ‘tailored therapies’ – an essential component of personalized medicine – to identify patients who are most likely to respond to therapy, and just as importantly, which patients will not.”
He added: “With ASCO studies focusing on non-small cell lung cancer, breast cancer, cervical cancer and biliary tract cancer, among others, Lilly will demonstrate its continued commitment to meeting the needs of patients across a broad oncology spectrum.”
1 user commented in " Eli Lilly to Unveil Study Data "
Follow-up comment rss or Leave a TrackbackEli Lilly has made $38 billion on Zyprexa and it was way oversold and caused diabetes and in some cases sudden death.
Lilly still criminal on Zyprexa
Please do a report on Lilly’s (NOW up to $4.6 billion) Zyprexa setllement payout is being stonewalled. 8 Lilly employees who are supposed ‘whistleblowers’ are getting $ 10 million each the real victims like me are being ignored.
I am a living example of Zyprexa gone/done wrong was given it 1996-2000 off-label for PTSD got sudden high blood sugar A1C 14.7 in January 2000.The stuff was worthless for my condition PTSD and cost me thousands in co-pays gave me diabetes.
—
Daniel Haszard
Leave A Reply